Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.
ESPs containing Healx
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The clinical study & protocol design market focuses on designing and planning clinical trials and research studies. This market offers a range of solutions to develop study protocols that adhere to ethical guidelines, regulatory requirements, and scientific rigor. By engaging in the clinical study & protocol design market, organizations and researchers can ensure that studies generate reliable and…
Healx's Products & Differentiators
New rare or common disease predictions for human safe compounds. Our technology can be applied to marketed, development or shelved compounds. Healx performs prediction and early pharmacological validation of predictions.
Research containing Healx
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Healx in 1 CB Insights research brief, most recently on May 17, 2022.
Expert Collections containing Healx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Healx is included in 5 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 150
The winners of the second annual CB Insights Digital Health 150.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Healx has filed 10 patents.
Phosphodiesterase inhibitors, Lactams, Amines, Beta blockers, Piperazines
Phosphodiesterase inhibitors, Lactams, Amines, Beta blockers, Piperazines
Latest Healx News
May 8, 2023
Meet the European startups using GenAI in healthcare and drug discovery 8 min read Since ChatGPT’s launch last year, large language models (LLMs) have mostly drawn attention for helping non-engineers write code and explaining quantum computing to five-year-olds. Less well-known is the fact that LLMs are already being used widely in healthcare — Sifted has identified a number of European startups using generative AI-powered tools that are already being used in millions of real-life care situations. The tools range from doctor-patient interaction analysis to new drug creation. Wider use of AI in healthcare has been facilitated by better access to large volumes of structured data to train models on, and better hardware to carry out AI model training. Advertisement “Within a few years, we will have AI that is better at doing this groundwork [in diagnosing a patient]. There is where the generative models come in,” Matilda Andersson, a machine learning engineer active in healthcare, tells Sifted. “A lot is about being able to do analyses that are too complex for humans. No human can go through 5m data points — we don't have that ability or the time,” she says. “Physicians are already under a huge time constraint.” Eavesdropping on patients One use case for models like these is to listen in on patient-doctor meetings and help physicians deliver the right diagnosis and treatment. Spoken interactions always present the issue of interpretation, and depending on what patients tell medical staff, they can get the wrong treatment. Danish AI startup Corti has focused on augmenting human conversation in healthcare with generative AI since 2018. The company started by learning from recordings of emergency medical phone calls involving cardiac arrest — now its technology is used by hospitals and other healthcare institutions in Scandinavia, the UK and the US in over 50m patient encounters per year. “We've built on the thesis of building generative models from the very get-go of Corti’s history. We can take those large language models, then we fine-tune them with some different architectural choices to fit our vertical,” says Lars Maaløe, machine learning professor and one of the cofounders of Corti. Sifted Newsletters Join to Sign Up GenAI for admin UK home care platform Cera, which helps elderly patients and their carers manage at-home healthcare, is putting AI to use in simplifying care plan preparation. Cera’s care providers put these together when sending patients home from the hospital. Based on conversations between medical professionals and patients and a house visit, they can take as much as 12 hours in total to put together, according to Cera’s founder and CEO Ben Maruthappu. They’re also usually written by hand. Cera plans to use AI to convert a conversation recorded on a care assessor’s phone into a care plan automatically, reducing the process to a couple of hours. OpenAI backer Microsoft is providing the foundation models and applications for Cera, which plans to roll out the service on a few thousand patients in southeast England over the next few months. Foundation models, like GPT-3 and DALL-E, are trained on a broad set of unlabelled data that can be used for different tasks but can be fine-tuned for healthcare purposes. Cera also plans to introduce an AI-powered task recommendation tool for care assistants this year which will suggest certain treatments and support decisions. LLM for drug discovery Another major use case for LLMs in healthcare is drug discovery. Several of these companies exist in Europe; there’s LabGenius and Healx in the UK and Cradle in the Netherlands. Advertisement Cradle’s CEO Stef van Grieken previously worked in the product leadership team at Google Research where he was involved in early work on large language models. Now, he’s helping the company improve protein design, which can be used, for example, in discovering new antibodies for pharmaceuticals. “At Cradle, instead of applying these types of techniques to natural language, we try to use it to understand the language of biology,” van Grieken says. “Instead of ChatGPT, where you give it a prompt, and you get an answer, in our case, you say, ‘I would like to catalyse this chemical reaction’ or ‘I would like to bind to this thing’ or ‘I would like it to be more stable under a higher temperature'." The proteins that Cradle generates can then be tested by other researchers in their laboratories. “Maybe one in 1,000 sequences that [humans] try in the lab will do what they want or what they intended at the start,” van Grieken says. “By using these large language models to come up with much better alternatives, the number of experiments that you need to do in order to get to a working product goes down dramatically.” Leonard Wossnig, CTO at LabGenius Healx is using LLMs to come up with new compounds — chemical structures that have the potential to one day become drugs. It does this by feeding the model everything Healx knows about a compound, including both public and proprietary data. “One compound [we were investigating] was likely to be effective, and we understood which parts of the molecule were aiding treatment — but it was highly toxic,” says Bill Tatsis, a scientist at Healx. “The team used generative AI models to produce the molecule with similar efficacy with less toxicity.” LabGenius, which repurposes antibodies to specifically tackle cancer cells, is now looking into applying AI methods in the earlier drug discovery stages — specifically to find good binders for the drugs, says CTO Leonard Wossnig. “Good binding molecules are something that we already have methods for finding today, but they are slow. I think gen AI will speed up these solutions,” he says. The risks of using GenAI in healthcare As with any new technology, some are worried about LLMs being used broadly in healthcare. Models are often only as good as the data they are trained on. “Over-reliance [on AI] is a risk,” says Cera’s Maruthappu. “People can become over-reliant on tech, even if they have medical qualifications. That's why it’s important to have controls and checks to make sure people don’t take their hands off the steering wheel.” Claire Novorol, cofounder and chief medical officer at Ada Health, worries about the bias of data that LLMs are trained on and hallucinations. Hallucinations happen when the AI generates outputs that don’t reflect data inputs, like when AI gives a response that is factually inaccurate. “These hallucinations are basically providing responses, many of which might be quite appropriate, but some of which are completely inappropriate, completely untrue, completely fabricated but provided with the same level of extreme confidence — obviously, a non-expert would not be able to differentiate between the two,” Novorol says. Claire Novorol, cofounder and chief medical officer at Ada Health Instead of a generative model, Ada has built a proprietary symptom tracker over the last 10 years on a probability model, developed in conjunction with a large team of medical doctors. And although Ada is looking into how AI can be used within its triage system, Novorol wouldn’t consider using one of the foundation models, such as GPT, since she wouldn’t be confident in how it was built and how truthful it would be. “Increasingly there will be models that are specifically trained on more and more medical data, and I think a lot of the problems will be reduced. It is not yet known that they can be completely eliminated though. Those hallucinations are something kind of fundamental to the system. It's fundamentally linked to how these systems work and their strengths,” she says. But according to van Grieken at Cradle, the need for an AI's outputs to be on par with people when it comes to truthfulness isn't always necessary given how poor human understanding is of DNA. “In biology, we've compared against some of the methods that people are using in science today and we've been able to demonstrate that [our GenAI model] significantly outperforms what humans can do. And obviously, as more data comes in, and as we learn more about this problem, the better our models get,” he says. Stef van Grieken, CEO of Cradle And of course, molecules discovered using AI wouldn’t be rolled out straight from the lab to the pharmacy — they would go through rigorous testing and clinical trials before actually making it to market. In addition, models have improved quickly in the space of healthcare. An early version of Google's medical LLM Medpalm scored less than 60% on a doctor's exam (still a pass) — but a later version got an “expert” mark of 85%. Slow transformation but overhyped all the same While generative AI has the potential to “transform” healthcare eventually, adoption of it in the larger healthcare sector will take time. “In five to ten years, generative AI will be part of day-to-day medical practice, but we’re quite far from that,” Cera’s Maruthappu says. “Healthcare is regulated, which means that as we've seen with digital technologies and the use of data in healthcare in the past, it's not going to be a radical transformation that happens in a year.” On the other hand, others think generative AI in healthcare is “overhyped”. One is Marta-Gaia Zanchi, partner at healthtech-focused VC Nina Capital, who thinks it's becoming a buzzword for startups in the sector (and in other fields ). “Startups start pitching their generative AI-based solution and they don’t really have a good answer for why they need to use generative AI,” she tells Sifted. “Applying generative AI without regard to what the right solution means skipping the most important step in the innovation process and just building elaborate skyscrapers on a very weak foundation,” Zanchi says. Advertisement
Healx Frequently Asked Questions (FAQ)
When was Healx founded?
Healx was founded in 2014.
Where is Healx's headquarters?
Healx's headquarters is located at Charter House, 66-68 Hills Rd, Cambridge.
What is Healx's latest funding round?
Healx's latest funding round is Incubator/Accelerator.
How much did Healx raise?
Healx raised a total of $66.38M.
Who are the investors of Healx?
Investors of Healx include Tech Nation Fintech, Jonathan Milner, Amadeus Capital Partners, Balderton Capital, Intel Capital and 6 more.
Who are Healx's competitors?
Competitors of Healx include Verge Genomics, Cyclica, BERG, BenevolentAI, Biotx.ai and 14 more.
What products does Healx offer?
Healx's products include Indication expansion and 3 more.
Who are Healx's customers?
Customers of Healx include Ovid Therapeutics.
Compare Healx to Competitors
Insitro provides data-driven drug discovery and development solutions. It combines machine learning and modern biological tools to enable predictive models. The company was founded in 2018 and is based in South San Francisco, California.
Aitia use causal AI and Digital Twins to discover the next generation of drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology, neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover new therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia was founded in 2000 and is based in Somerville, Massachusetts.
Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that discovers and develops novel small molecule therapies for complex and hard-to-treat diseases
Standigm is an AI and systems biology-based startup that aims to expedite the drug discovery process. Standigm develops a computer modeling technology that learns medical and biological information and predicts the action mechanism of pharmaceutics in advance. This technology can improve the pharmaceutical development process by tailoring the application of previous know-hows, come up with possible combinations of pharmaceuticals, and optimize the selection of candidates and participants for clinical trials.
BioMap specializes in research and development (R&D) and in early screening, diagnosis, drug discovery and other precision medicine products through biocomputing and artificial intelligence (AI).